Financial Performance - The company's operating revenue for 2021 was ¥529,615,447.55, representing an increase of 8.05% compared to ¥490,164,744.19 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥68,507,883.04, a decrease of 25.53% from ¥91,988,592.72 in 2020[18]. - The net cash flow from operating activities was ¥48,149,282.18, down 24.34% from ¥63,639,874.30 in the previous year[18]. - Basic earnings per share for 2021 were ¥1.05, a decline of 31.37% compared to ¥1.53 in 2020[18]. - The total assets at the end of 2021 amounted to ¥851,423,622.82, an increase of 129.49% from ¥371,006,145.17 at the end of 2020[18]. - The net assets attributable to shareholders reached ¥792,918,557.15, up 227.16% from ¥242,361,001.66 in 2020[18]. - The company reported a weighted average return on equity of 17.25% for 2021, down from 46.85% in 2020[18]. - The gross profit margin for the pharmaceutical manufacturing industry was 88.61%, a decrease of 2.34% compared to the previous year[49]. - The total operating cost for the pharmaceutical manufacturing sector was CNY 60,327,111.01, reflecting a year-on-year increase of 35.91%[49]. Revenue Sources - The core product, Sodium Acetate Ringer's Injection, generated sales revenue of ¥465,358,327.89, accounting for 87.87% of total revenue during the reporting period[34][37][43]. - The company achieved sales revenue of ¥64,257,119.66 from Cefotaxime Sodium Injection, representing 12.13% of total revenue[34][37]. - The company’s core product has not yet been included in the national volume-based procurement list, which may affect its sales dynamics in key regions[31]. - The company relies heavily on Sodium Acetate Ringer's Injection for revenue, posing a risk if it cannot maintain its market position or if new product development does not meet expectations[40][42]. Market and Product Development - The company has developed a new production technology for colloidal solutions, which reduces production costs and time while ensuring high product quality[33]. - The company is advancing multiple R&D projects, including sodium bicarbonate injection and venlafaxine sustained-release capsules, aimed at enhancing its product line and market competitiveness[62]. - The company is accelerating the development of new products in the fields of plasma substitutes, emergency medications, pediatric medications, and psychiatric medications to diversify its revenue sources[86]. - The company has established a marketing network covering 29 provinces and municipalities, with its main products sold in over 800 hospitals nationwide, including more than 500 tertiary hospitals[35][41]. Research and Development - The company has 64 R&D personnel, accounting for 21.40% of total employees, indicating a strong focus on research and development[44]. - The company has obtained 48 patents, including 10 invention patents, 36 utility model patents, and 2 design patents, with 8 invention patents currently under application[34][42]. - The number of R&D personnel decreased by 4.48% to 64 from 67 in the previous year, with a slight increase in the proportion of bachelor's degree holders[63]. Cash Flow and Investments - Operating cash inflow totaled CNY 611,479,125.47, a 4.25% increase from CNY 586,564,676.94[64]. - Investment cash outflow surged by 323.71% to CNY 215,345,754.75 from CNY 50,823,985.30[64]. - Financing cash inflow increased significantly by 1,257.85% to CNY 557,803,960.00 from CNY 41,080,000.00[64]. - The net increase in cash and cash equivalents was CNY 376,278,639.03, a dramatic rise of 4,126.68% from CNY 8,902,460.58[64]. Corporate Governance - The company maintained independence from its controlling shareholders in business, personnel, assets, institutions, and finance, ensuring a complete and autonomous operational capability[96]. - The company has established a sound financial and accounting management system, with independent accounting professionals managing financial records and making financial decisions[97]. - The company has a total of 7 board members, including 3 independent directors[109]. - The company has a robust internal control system that will continue to be optimized for healthy operations[95]. Employee and Management - The total number of employees at the end of the reporting period was 299, with 107 in the parent company and 192 in major subsidiaries[121]. - The company emphasizes employee training and development, with plans to enhance vocational skills and cultivate high-level talent in 2022[123]. - The total remuneration for the chairman and general manager, Mr. Deng Yong, was CNY 741,500[110]. Dividend Policy - The company plans to conduct at least one profit distribution annually, with cash distribution preferred, contingent on meeting certain financial conditions[126]. - The company proposed a cash dividend of 6.25 CNY per 10 shares, totaling 50,000,000 CNY (including tax) for the reporting period[133]. - The total distributable profit for the year was 115,955,981.72 CNY, with the cash dividend representing 100% of the profit distribution[133]. Social Responsibility and Compliance - The company actively engages in corporate social responsibility, including donations to local schools in Changdu, Tibet, to support underprivileged students[146]. - The company emphasizes compliance with environmental laws and has established internal standards for environmental protection, with no pollution incidents reported[144]. - The company has committed to long-term stability in its shareholding structure, with no plans for share transfers during the lock-up period[149].
多瑞医药(301075) - 2021 Q4 - 年度财报